A Meta-analysis of Methods to Prevent Venous Thromboembolism Following Total Hip Replacement

JAMA: The Journal of the American Medical Association

Volumn 271, Issue 22, 1994, Pages 1780-1785

  Imperiale, Thomas F ^a   Speroff, Theodore ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN III; DEXTRAN; DIHYDROERGOTAMINE MESILATE; HEPARIN; WARFARIN;

ADULT; AGED; BLEEDING; CLINICAL TRIAL; COMPRESSION THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG EMBOLISM; MALE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS;

EID: 0028284442     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1994.03510460072036     Document Type: Article

References (80)

1. Goldhaber SZ. Prevention of venous thromboembolism. In: Goldhaber SZ, ed. Pulmonary Embolism and Deep Venous Thrombosis. Philadelphia, Pa: WB Saunders Co; 1985:135-157.
2. O'Meara PM, Kauman EE. Prophylaxis for venous thromboembolism is total hip arthroplasty: a review. Orthopedics. 1990;13:173-178.
3. Parker-Williams J, Vicker R. Major orthopedic surgery on the leg and thromboembolism. BMJ. 1991;303: 531-532.
4. Brenkel IJ, Clancy MJ. Total hip replacement and antithrombotic prophylaxis. Br J Hosp Med. 1989;42: 282-284.
5. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second line drugs in rheumatoid arthritis. Arthritis Rheum. 1990:33:1449-1461.
6. Chalmers TC, Smith H Jr, Blackburn B, et al. A method for assessing the quality of a randomized controlled trial. Controlled Clin Trials. 1981;2:31-49.
7. Gerbarg ZB, Horwitz RI. Resolving conflicting clinical trials: guidelines for meta-analysis. J Clin Epidemiol. 1988;41:503-509.
8. DerSimonian R, Laird NM. Combining evidence in clinical trials. Controlled Clin Trials. 1986;7:177-188.
9. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6:5-30.
10. Hedges LV. Meta-analysis. J Educ Stat. 1992;17: 279-296.
11. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141-151.
12. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
13. SAS Language Guide for Personal Computers, Release 6.03 Edition. Cary, NC: SAS Institute Inc; 1988.
14. Hampson WGS, Harris FC, Lucas HK, et al. Failure of low dose heparin to prevent deep-vein thrombosis after hip-replacement arthroplasty. Lancet. 1974;2: 795-797.
15. Morris GK, Henry APJ, Preston BJ. Prevention of deep-vein thrombosis by low-dose heparin in patients undergoing total hip replacement. Lancet. 1974;2:797-800.
16. Sagar S, Nairn D, Stamatakis JD, et al. Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total hip replacement. Lancet. 1976;1:1151-1154.
17. Alfaro MJ, Paramo JA, Rocha E. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. Thromb Haemost. 1986;56:53-56.
18. Venous Thrombosis Clinical Study Group. Small doses of subcutaneous sodium heparin in the prevention of deep vein thrombosis after elective hip operations. Br J Surg. 1975;62:348-350.
19. Leyvraz PF, Richard J, Bachmann F, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 1983;309:954-958.
20. Rogers PH, Walsh PN, Marder VS, et al. Controlled trial of low-dose heparin and sulfinpyrazone to prevent venous thromboembolism after operation on the hip. J Bone Joint Surg Am. 1978;60:758-762.
21. Beisaw NE, Comerota AJ, Groth HG, et al. Dihydroergotamine/heparin in the prevention of deepvein thrombosis after total hip repalcement. J Bone Joint Surg Am. 1988;70:2-10.
22. Morris WT, Hardy AE, The effect of dihydroergotamine and heparin on the incidence of thromboembolic complications following total hip repalcement. Br J Surg. 1981;68:301-303.
23. Lassen MR, Borris LC, Christiansen HM, Moller-Larsen F. Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery. Br J Surg. 1988;75:686-689.
24. Josefsson G, Dahlqvist A, Bodfors B. Prevention of thromboembolism in total hip replacement. Acta Orthop Scand. 1987;58:626-629.
25. Mannucci PM, Citterio LE, Panajotopoulos N. Low-dose heparin and deep-vein thrombosis after total hip replacement. Thromb Haemost. 1976;36:157-164.
26. Fredin HO, Rosberg B, Arborlius M Jr, Nylander G. On thromboembolism after total hip replacement in epidural analgesia: controlled study of dextran 70 and low-dose heparin combined with dihydroergotamine. Br J Surg. 1984;71:58-60.
27. Schondorf TH, Hey D. Modified 'low-dose' heparin prophylaxis to reduce thrombosis after hip joint operations. Thromb Res. 1977;12:153-163.
28. Barber HM, Feil EJ, Galasko CSB, et al. A comparative study of dextran-70, warfarin and low-dose heparin for the prophylaxis of thromboembolism following total hip replacement. Postgrad Med J. 1977;53: 130-133.
29. Francis CW, Pellegrini VD, Marder VJ, et al. Prevention of venous thrombosis after total hip arthroplasty. J Bone Joint Surg Am. 1989;71:327-335.
30. Leyvraz P, Bachmann F, Vuilleumier B, Berthet S, Bohnet J, Haller E. Adjusted subcutaneous heparin versus heparin plus dihydroergotamine in prevention of deep vein thrombosis after total hip arthroplasty. J Arthroplasty. 1988;3:81-86.
31. Moskovitz PA, Ellenberg SS, Feffer HL, Kenmore PI. Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg Am. 1978;60: 1065-1069.
32. Flicoteaux H, Kher A, Jean N, et al. Comparison of low-dose heparin combined with aspirin in prevention of deep vein thrombosis after total hip replacement. Pathol Biol (Paris). 1977;25(suppl):55-58.
33. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991;303: 543-548.
34. Haas S, Steinberger A, Fritsche HM, et al. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Drug Res. 1987;37:839-843.
35. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. Ann Intern Med. 1991;114:545-551.
36. Planes A, Vochelle N, Fagola M, Feret J, Bellaud M. Prevention of deep-vein thrombosis after total hip replacement. J Bone Joint Surg Am. 1991;73: 418-421.
37. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315:925-929.
38. The Danish Enoxaparin Study Group. Low-molecular-weight heparin (enoxaparin) vs dextran-70. Arch Intern Med. 1991;151:1621-1624.
39. Planes A, Vochelle N, Mazas F, Mansat C. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988;60:407-410.
40. Lassen MR, Lars CB, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties. Acta Orthop Scand. 1991;62:33-38.
41. Matzsch T, Bergqvist D, Fredin H, Hedner U. Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand. 1990;156:445-450.
42. Freick H, Haas S. Prevention of deep vein thrombosis by low-molecular-weight heparin and dihydroergotamine in patients undergoing total hip replacement. Thromb Res. 1991;63:133-143.
43. Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B. Thrombosis prophylaxis with low molecular weight heparin in hip replacement. Br J Surg. 1988;75: 1053-1057.
44. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis. 1989;1:5-12.
45. Eriksson BI, Kalebo P, Anthmyr BA, et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg Am. 1991;73:484-493.
46. Bergqvist D, Efsing HO, Hallbook T, Hedlund T. Thromboembolism after elective and post-traumatic hip surgery: a controlled prophylactic trial with dextran 70 and low-dose heparin. Acta Chir Scand. 1979; 145:213-218.
47. Harris WH, Salzman EW, DeSanctis RW, Coutts RD. Prevention of venous thromboembolism following total hip replacement. JAMA. 1972;220:1319-1322.
48. Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. Prophylaxis of deep-vein thrombosis after total hip replacement. J Bone Joint Surg Am. 1985;67: 57-62.
49. Francis CW, Marder VS, McCollister-Evarts C, Yaukoolbodi S. Two-step warfarin therapy. JAMA. 1983;249:374-378.
50. Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med. 1977;297:1246-1249.
51. Sautter RD, Koch EL, Myers WO, et al. Aspirinsulfinpyrazone in prophylaxis of deep venous thrombosis in total hip replacement. JAMA. 1983;250:2649-2654.
52. Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. High and low dose aspirin prophylaxis against venous thromboembolism disease in total hip replacement. J Bone Joint Surg Am. 1982;64:63-66.
53. Harris WH, Salzman EW, DeSanctis RW. The prevention of thromboembolic disease by prophylactic anticoagulation. J Bone Joint Surg Am. 1967;49: 81-89.
54. Harris WH, Salzman EW, Athanasoulis C, Waltman AC, Baum S, DeSanctis RW. Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. J Bone Joint Surg Am. 1974;56:1552-1562.
55. Bergqvist D, Lindblad B, Ljungstrom K-G, Persson NH, Hallbook T. Does dihydroergotamine potentiate the thromboprophylactic effect of dextran 70? a controlled prospective study in general and hip surgery. Br J Surg. 1984;71:516-521.
56. Rothermal JE, Wessinger JB, Stinchfield FE. Dextran 70 and thromboembolism in total hip replacement. Arch Surg. 1973;106:135-137.
57. Fordyce MJF, Baker AS, Staddon GE. Efficacy of minidose warfarin prophylaxis in total hip replacement. BMJ. 1991;303:219-220.
58. Evarts CM, Feil EJ. Prevention of thromboembolic disease after elective surgery of the hip. J Bone Joint Surg Am. 1971;53:1271-1280.
59. Fredin H, Bergqvist D, Cederholm C, Lindblad B, Nyman U. Thromboprophylaxis in hip arthroplasty. Acta Orthop Scand. 1989;60:678-681.
60. Ishak MA, Morley KD. Deep venous thrombosis after total hip arthroplasty: a prospective controlled study to determine the prophylactic effect of graded pressure stockings. Br J Surg. 1981;68:429-432.
61. Barnes RW, Brand RA, Clarke W, Hartley N, Hoak JC. Efficacy of graded-compression antiembolism stockings in patients undergoing total hip arthroplasty. Clin Orthop Related Res. 1978;132:61-67.
62. Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep-vein thrombosis after total hip replacement. JAMA. 1990;263:2313-2317.
63. Kaempffe FA, Lifeso RM, Meinking C. Intermittent pneumatic compression vs coumadin. Clin Orthop Rel Res. 1991;269:89-97.
64. Francis CW, Pellegrini VD, Marder VS, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992;267:2911-2915.
65. Woolson ST, Watt JM. Intermittent pneumatic compression to prevent proximal deep venous thrombosis during and after total hip replacement. J Bone Joint Surg Am. 1991;73:507-512.
66. Laguardia AM, Caroli GC. Prevention of deep vein thrombosis in orthopedic surgery: comparison of two different treatment protocols with low molecular weight heparin. Curr Med Res Opin. 1992;12:584-593.
67. Torholm C, Broeng L, Jorgensen PS, et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. J Bone Joint Surg Br. 1991;73: 434-438.
68. Hoek JA, Nurmohamed MT, Hamelynck KJ, et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost. 1992;67:28-32.
69. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993;329:1370-1376.
70. Turpie AG. Enoxaparin prophylaxis in elective hip surgery. Acta Chir Scand Suppl. 1990;556:103-107.
71. Planes A, Vochelle N, Fagola M, et al. Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep vein thrombosis after total hip replacement. Acta Chir Scand Suppl. 1990;556:108-115.
72. Matzsch T, Bergqvist D, Fredin H, Hedner U. Safety and efficacy of a low molecular weight heparin (logiparan) versus dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand Suppl. 1988;543:80-84.
73. O'Meara PM, Kaufman EE. Prophylaxis for venous thromboembolism in total hip arthroplasty: a review. Orthopedics. 1990;13:173-178.
74. Vitoux JF, Aiach M, Roncato M, Fiessinger JN. Should thromboprophylactic dosage of low molecular weight heparin be adapted to patient's weight? Thromb Haemost. 1988;59:120.
75. Kroon C, de Boer A, Kroon JM, et al. Influence of skinfold thickness on heparin absorption. Lancet. 1991; 337:945-946.
76. Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratio causes significant errors in anticoagulation therapy. Arch Intern Med. 1992;152:278-282.
77. Ransohoff DR, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978;299:926-930.
78. Angell M. Negative studies. N Engl J Med. 1989; 321:464-466.
79. Salzman EW, Davies GC. Prophylaxis of venous thromboembolism: analysis of cost-effectiveness. Ann Surg. 1980;191:207-218.
80. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA. 1987; 257:203-208.